January 23, 2017 06:48 AM EST
R&D

Deep in talks with J&J, Acte­lion’s flag­ship drug cruis­es past a piv­otal tri­al fail­ure

John Carroll

Editor & Founder

Deep in­to ne­go­ti­a­tions with J&J over a prospec­tive buy­out, Acte­lion (SIX: ATLN) re­port­ed to­day that its up-and-com­ing flag­ship ther­a­py Op­sum­it flunked a piv­otal test …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times